Eldecalcitol reduces risk of vertebral fractures in osteoporotic patients
A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind studyBone. 2011 Oct;49(4):605-12. doi: 10.1016/j.bone.2011.07.011. Epub 2011 Jul 19
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
1087 patients were randomized to determine the difference between two vitamin D analogs on the reduction of vertebral fractures in osteoporotic patients. Enrolled patients were allocated to receive eldecalcitol or alfacalcidol once daily, and were followed for 3 years. The results indicated that eldecalcitol reduced the risk of vertebral and wrist fractures, improved lumbar spine and total hip bon...
Join the Conversation
Please Login or Join to leave comments.